Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 15Ovarian Neoplasms 5Brain Neoplasms 4Neoplasms 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Breast Cancer 2Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-negative Metastatic Breast Cancer 1

Interventions

Trastuzumab 2liposomal doxorubicin 1eribulin 1Metformin 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER-2 Positive Breast Cancer × eribulin × Breast × Clear all
NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Vector Oncology

Phase 1/2 Terminated
12 enrolled 12 charts
Breast

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡